

Regd. Office :

'Zydus Tower',
Satellite Cross Roads,
Ahmedabad 380 015. India.
Phone : +91-79-2686 8100 (20 Lines)
Fax : +91-79-2686 2368
www.zyduscadila.com
CIN:L24230GJ1995PLC025878

BSE Limited 1st Floor, P.J. Towers Dalal Street <u>Mumbai – 400 001</u> Kind Attn.: Mr. Sanjay Golecha / Mr. Gopalkrishnan	National Stock Exchange of India Limited Exchange Plaza, 5th Floor, Plot No. C/1, G Block, Bandra-Kurla Complex, Bandra (East) <u>Mumbai – 400 051</u> Kind Attn.: Famroze Pochara Asst. Vice President
Date: July 11, 2016	
Re.: Press Release.	

Dear Sir / Madam,

We enclose herewith a copy of press release dated July 11, 2016, titled “**Zydus receives final approval from the USFDA for Nateglinide Tablets USP**, which will be produced at the group’s formulations manufacturing facility at the Pharma SEZ in Ahmedabad.” The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors’ at large.

Thanking you,

Yours faithfully,
For, Cadila Healthcare Limited


Upen H. Shah
Company Secretary



Encl.: As above.

Zydus receives final approval from the USFDA for Nateglinide Tablets USP

Ahmedabad, 11 July 2016

Zydus Cadila has received the final approval from the USFDA to market Nateglinide Tablets USP in strengths of 60 mg and 120 mg.

The drug is an oral anti-diabetic agent used in the management of Type 2 diabetes mellitus and will be produced at the group's formulations manufacturing facility at the Pharma SEZ in Ahmedabad.

The group now has more than 100 approvals and has so far filed nearly 270 ANDAs since the commencement of the filing process in FY 2003-04.
